Tocilizumab

Generic Name: Tocilizumab

Brand Names: Actemra, RoActemra, Tyenne, Tofidence

Drug Type: Biotech

Chemical Formula: -

CAS Number: 375823-41-9

Unique Ingredient Identifier: I031V2H011

Background: Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication: Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: Monotherapy

Clinical Trials

A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: Tocilizumab

First Posted Date: 2021-12-20

Last Posted Date: 2024-04-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT05164133

Locations: 🇿🇦
Global Clinical Trials Sunnyside, Pretoria, South Africa
🇪🇸
Hospital Sant Joan de Deu - PIN; Unitat de Recerca - Farmacia, Esplugues de Llobregat, Barcelona, Spain
🇪🇸
Hospital Infantil Universitario Niño Jesus; Sección de Neuropediatria, Madrid, Spain

and more 22 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Phase 1

Active, not recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Mosunetuzumab
Drug: Tocilizumab

First Posted Date: 2021-12-13

Last Posted Date: 2024-10-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT05155345

Locations: 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇵🇱
Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland
🇵🇱
Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM; Oddzial Reumat Rehab i Chorob Wewnetrznych, Poznan, Poland

and more 2 locations

High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19

Phase 4

Withdrawn

Conditions: Cytokine Storm
Corticosteroid
Tocilizumab
COVID-19 Virus Infection

Interventions: Drug: Methylprednisolone
Drug: Tocilizumab

First Posted Date: 2021-11-24

Last Posted Date: 2021-11-24

Lead Sponsor: Marmara University

Registration Number: NCT05133635

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: RO7444973
Drug: Tocilizumab

First Posted Date: 2021-11-22

Last Posted Date: 2023-08-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT05129280

Locations: 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇦🇺
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia

and more 7 locations

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1

Recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Mosunetuzumab
Drug: Tocilizumab
Drug: Venetoclax

First Posted Date: 2021-10-25

Last Posted Date: 2024-12-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 137

Registration Number: NCT05091424

Locations: 🇰🇷
Seoul St Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 18 locations

Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

Not Applicable

Completed

Conditions: COVID-19

Interventions: Drug: Tocilizumab
Drug: Baricitinib

First Posted Date: 2021-10-19

Last Posted Date: 2023-11-29

Lead Sponsor: University Hospital of Patras

Target Recruit Count: 251

Registration Number: NCT05082714

Locations: 🇬🇷
University Hospital of Patras, Department of Respiratory Medicine, Patras, Greece

The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia

Completed

Conditions: COVID-19 Pneumonia
ARDS

Interventions: Drug: Tocilizumab

First Posted Date: 2021-09-05

Last Posted Date: 2023-04-11

Lead Sponsor: Sciberras, Stephen M.D.

Target Recruit Count: 100

Registration Number: NCT05035589

Locations: 🇲🇹
Mater Dei Hospital, Imsida, Malta

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: Glofitamab
Drug: Tocilizumab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Rituximab
Drug: Cyclophosphamide

First Posted Date: 2021-07-28

Last Posted Date: 2024-12-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 46

Registration Number: NCT04980222

Locations: 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Stanford Cancer Center, Palo Alto, California, United States

and more 24 locations